Several potent PDGFRβ inhibitors, such as sunitinib, imatinib, nilotinib and sorafenib, have been developed for treating malignancies including chronic myelogenous leukemia (CML) [44], renal cell carcinoma (RCC) [45] and hepatocellular carcinoma (HCC) [46]. This evidence concerns the gene PDGFRB and renal cell carcinoma.